The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
DTaP and Tdap Vaccines-Global Market Insights and Sales Trends 2025
Synopsis
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.
Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.
The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
The global DTaP and Tdap Vaccines market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of DTaP and Tdap Vaccines in various end use industries. The expanding demands from the Adult and Pediatric, are propelling DTaP and Tdap Vaccines market. DTaP, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Td segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for DTaP and Tdap Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global DTaP and Tdap Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global DTaP and Tdap Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, DTaP and Tdap Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of DTaP and Tdap Vaccines covered in this report include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Inc, Pfizer Inc and Johnson & Johnson, etc.
The global DTaP and Tdap Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US, Inc
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Global DTaP and Tdap Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global DTaP and Tdap Vaccines market, Segment by Type:
DTaP
Td
Tdap
Global DTaP and Tdap Vaccines market, by Application
Adult
Pediatric
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of DTaP and Tdap Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF’s total procurement.
Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries.
The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%–85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people.
The global DTaP and Tdap Vaccines market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of DTaP and Tdap Vaccines in various end use industries. The expanding demands from the Adult and Pediatric, are propelling DTaP and Tdap Vaccines market. DTaP, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Td segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for DTaP and Tdap Vaccines, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global DTaP and Tdap Vaccines market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global DTaP and Tdap Vaccines market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, DTaP and Tdap Vaccines sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of DTaP and Tdap Vaccines covered in this report include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Inc, Pfizer Inc and Johnson & Johnson, etc.
The global DTaP and Tdap Vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US, Inc
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Global DTaP and Tdap Vaccines market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global DTaP and Tdap Vaccines market, Segment by Type:
DTaP
Td
Tdap
Global DTaP and Tdap Vaccines market, by Application
Adult
Pediatric
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of DTaP and Tdap Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of DTaP and Tdap Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 DTaP and Tdap Vaccines Market Overview
1.1 DTaP and Tdap Vaccines Product Overview
1.2 DTaP and Tdap Vaccines Market Segment by Type
1.2.1 DTaP
1.2.2 Td
1.2.3 Tdap
1.3 Global DTaP and Tdap Vaccines Market Size by Type
1.3.1 Global DTaP and Tdap Vaccines Market Size Overview by Type (2018-2029)
1.3.2 Global DTaP and Tdap Vaccines Historic Market Size Review by Type (2018-2023)
1.3.3 Global DTaP and Tdap Vaccines Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America DTaP and Tdap Vaccines Sales Breakdown by Type (2018-2023)
1.4.2 Europe DTaP and Tdap Vaccines Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific DTaP and Tdap Vaccines Sales Breakdown by Type (2018-2023)
1.4.4 Latin America DTaP and Tdap Vaccines Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa DTaP and Tdap Vaccines Sales Breakdown by Type (2018-2023)
2 Global DTaP and Tdap Vaccines Market Competition by Company
2.1 Global Top Players by DTaP and Tdap Vaccines Sales (2018-2023)
2.2 Global Top Players by DTaP and Tdap Vaccines Revenue (2018-2023)
2.3 Global Top Players by DTaP and Tdap Vaccines Price (2018-2023)
2.4 Global Top Manufacturers DTaP and Tdap Vaccines Manufacturing Base Distribution, Sales Area, Product Type
2.5 DTaP and Tdap Vaccines Market Competitive Situation and Trends
2.5.1 DTaP and Tdap Vaccines Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by DTaP and Tdap Vaccines Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in DTaP and Tdap Vaccines as of 2022)
2.7 Date of Key Manufacturers Enter into DTaP and Tdap Vaccines Market
2.8 Key Manufacturers DTaP and Tdap Vaccines Product Offered
2.9 Mergers & Acquisitions, Expansion
3 DTaP and Tdap Vaccines Status and Outlook by Region
3.1 Global DTaP and Tdap Vaccines Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global DTaP and Tdap Vaccines Historic Market Size by Region
3.2.1 Global DTaP and Tdap Vaccines Sales in Volume by Region (2018-2023)
3.2.2 Global DTaP and Tdap Vaccines Sales in Value by Region (2018-2023)
3.2.3 Global DTaP and Tdap Vaccines Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global DTaP and Tdap Vaccines Forecasted Market Size by Region
3.3.1 Global DTaP and Tdap Vaccines Sales in Volume by Region (2024-2029)
3.3.2 Global DTaP and Tdap Vaccines Sales in Value by Region (2024-2029)
3.3.3 Global DTaP and Tdap Vaccines Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global DTaP and Tdap Vaccines by Application
4.1 DTaP and Tdap Vaccines Market Segment by Application
4.1.1 Adult
4.1.2 Pediatric
4.2 Global DTaP and Tdap Vaccines Market Size by Application
4.2.1 Global DTaP and Tdap Vaccines Market Size Overview by Application (2018-2029)
4.2.2 Global DTaP and Tdap Vaccines Historic Market Size Review by Application (2018-2023)
4.2.3 Global DTaP and Tdap Vaccines Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America DTaP and Tdap Vaccines Sales Breakdown by Application (2018-2023)
4.3.2 Europe DTaP and Tdap Vaccines Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific DTaP and Tdap Vaccines Sales Breakdown by Application (2018-2023)
4.3.4 Latin America DTaP and Tdap Vaccines Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa DTaP and Tdap Vaccines Sales Breakdown by Application (2018-2023)
5 North America DTaP and Tdap Vaccines by Country
5.1 North America DTaP and Tdap Vaccines Historic Market Size by Country
5.1.1 North America DTaP and Tdap Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America DTaP and Tdap Vaccines Sales in Volume by Country (2018-2023)
5.1.3 North America DTaP and Tdap Vaccines Sales in Value by Country (2018-2023)
5.2 North America DTaP and Tdap Vaccines Forecasted Market Size by Country
5.2.1 North America DTaP and Tdap Vaccines Sales in Volume by Country (2024-2029)
5.2.2 North America DTaP and Tdap Vaccines Sales in Value by Country (2024-2029)
6 Europe DTaP and Tdap Vaccines by Country
6.1 Europe DTaP and Tdap Vaccines Historic Market Size by Country
6.1.1 Europe DTaP and Tdap Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe DTaP and Tdap Vaccines Sales in Volume by Country (2018-2023)
6.1.3 Europe DTaP and Tdap Vaccines Sales in Value by Country (2018-2023)
6.2 Europe DTaP and Tdap Vaccines Forecasted Market Size by Country
6.2.1 Europe DTaP and Tdap Vaccines Sales in Volume by Country (2024-2029)
6.2.2 Europe DTaP and Tdap Vaccines Sales in Value by Country (2024-2029)
7 Asia-Pacific DTaP and Tdap Vaccines by Region
7.1 Asia-Pacific DTaP and Tdap Vaccines Historic Market Size by Region
7.1.1 Asia-Pacific DTaP and Tdap Vaccines Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific DTaP and Tdap Vaccines Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific DTaP and Tdap Vaccines Sales in Value by Region (2018-2023)
7.2 Asia-Pacific DTaP and Tdap Vaccines Forecasted Market Size by Region
7.2.1 Asia-Pacific DTaP and Tdap Vaccines Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific DTaP and Tdap Vaccines Sales in Value by Region (2024-2029)
8 Latin America DTaP and Tdap Vaccines by Country
8.1 Latin America DTaP and Tdap Vaccines Historic Market Size by Country
8.1.1 Latin America DTaP and Tdap Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America DTaP and Tdap Vaccines Sales in Volume by Country (2018-2023)
8.1.3 Latin America DTaP and Tdap Vaccines Sales in Value by Country (2018-2023)
8.2 Latin America DTaP and Tdap Vaccines Forecasted Market Size by Country
8.2.1 Latin America DTaP and Tdap Vaccines Sales in Volume by Country (2024-2029)
8.2.2 Latin America DTaP and Tdap Vaccines Sales in Value by Country (2024-2029)
9 Middle East and Africa DTaP and Tdap Vaccines by Country
9.1 Middle East and Africa DTaP and Tdap Vaccines Historic Market Size by Country
9.1.1 Middle East and Africa DTaP and Tdap Vaccines Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa DTaP and Tdap Vaccines Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa DTaP and Tdap Vaccines Sales in Value by Country (2018-2023)
9.2 Middle East and Africa DTaP and Tdap Vaccines Forecasted Market Size by Country
9.2.1 Middle East and Africa DTaP and Tdap Vaccines Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa DTaP and Tdap Vaccines Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Sanofi Pasteur
10.1.1 Sanofi Pasteur Company Information
10.1.2 Sanofi Pasteur Introduction and Business Overview
10.1.3 Sanofi Pasteur DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Sanofi Pasteur DTaP and Tdap Vaccines Products Offered
10.1.5 Sanofi Pasteur Recent Development
10.2 GlaxoSmithKline
10.2.1 GlaxoSmithKline Company Information
10.2.2 GlaxoSmithKline Introduction and Business Overview
10.2.3 GlaxoSmithKline DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.2.4 GlaxoSmithKline DTaP and Tdap Vaccines Products Offered
10.2.5 GlaxoSmithKline Recent Development
10.3 Protein Sciences Corporation
10.3.1 Protein Sciences Corporation Company Information
10.3.2 Protein Sciences Corporation Introduction and Business Overview
10.3.3 Protein Sciences Corporation DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Protein Sciences Corporation DTaP and Tdap Vaccines Products Offered
10.3.5 Protein Sciences Corporation Recent Development
10.4 Novartis AG
10.4.1 Novartis AG Company Information
10.4.2 Novartis AG Introduction and Business Overview
10.4.3 Novartis AG DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Novartis AG DTaP and Tdap Vaccines Products Offered
10.4.5 Novartis AG Recent Development
10.5 Seqirus
10.5.1 Seqirus Company Information
10.5.2 Seqirus Introduction and Business Overview
10.5.3 Seqirus DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Seqirus DTaP and Tdap Vaccines Products Offered
10.5.5 Seqirus Recent Development
10.6 Merck Sharp & Dohme Corp
10.6.1 Merck Sharp & Dohme Corp Company Information
10.6.2 Merck Sharp & Dohme Corp Introduction and Business Overview
10.6.3 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Merck Sharp & Dohme Corp DTaP and Tdap Vaccines Products Offered
10.6.5 Merck Sharp & Dohme Corp Recent Development
10.7 Astellas Pharma US, Inc
10.7.1 Astellas Pharma US, Inc Company Information
10.7.2 Astellas Pharma US, Inc Introduction and Business Overview
10.7.3 Astellas Pharma US, Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Astellas Pharma US, Inc DTaP and Tdap Vaccines Products Offered
10.7.5 Astellas Pharma US, Inc Recent Development
10.8 Pfizer Inc
10.8.1 Pfizer Inc Company Information
10.8.2 Pfizer Inc Introduction and Business Overview
10.8.3 Pfizer Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Pfizer Inc DTaP and Tdap Vaccines Products Offered
10.8.5 Pfizer Inc Recent Development
10.9 Johnson & Johnson
10.9.1 Johnson & Johnson Company Information
10.9.2 Johnson & Johnson Introduction and Business Overview
10.9.3 Johnson & Johnson DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Johnson & Johnson DTaP and Tdap Vaccines Products Offered
10.9.5 Johnson & Johnson Recent Development
10.10 Lanzhou Institute of Biological Products Co., Ltd
10.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
10.10.2 Lanzhou Institute of Biological Products Co., Ltd Introduction and Business Overview
10.10.3 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Lanzhou Institute of Biological Products Co., Ltd DTaP and Tdap Vaccines Products Offered
10.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Development
10.11 AstraZeneca
10.11.1 AstraZeneca Company Information
10.11.2 AstraZeneca Introduction and Business Overview
10.11.3 AstraZeneca DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.11.4 AstraZeneca DTaP and Tdap Vaccines Products Offered
10.11.5 AstraZeneca Recent Development
10.12 Emergent BioSolutions Inc
10.12.1 Emergent BioSolutions Inc Company Information
10.12.2 Emergent BioSolutions Inc Introduction and Business Overview
10.12.3 Emergent BioSolutions Inc DTaP and Tdap Vaccines Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Emergent BioSolutions Inc DTaP and Tdap Vaccines Products Offered
10.12.5 Emergent BioSolutions Inc Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 DTaP and Tdap Vaccines Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 DTaP and Tdap Vaccines Industrial Chain Analysis
11.4 DTaP and Tdap Vaccines Market Dynamics
11.4.1 DTaP and Tdap Vaccines Industry Trends
11.4.2 DTaP and Tdap Vaccines Market Drivers
11.4.3 DTaP and Tdap Vaccines Market Challenges
11.4.4 DTaP and Tdap Vaccines Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 DTaP and Tdap Vaccines Distributors
12.3 DTaP and Tdap Vaccines Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
